Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies

D Sermer, C Batlevi, ML Palomba, G Shah… - Blood …, 2020 - ashpublications.org
The prognosis of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma
(DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R …
被引用次数：99 相关文章

Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies

D Sermer, C Batlevi, ML Palomba, G Shah, RJ Lin… - Blood Advances, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> The prognosis of patients with relapsed or
refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is poor. Chimeric antigen receptor …
[HTML] nih.gov

[HTML][HTML] Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies

D Sermer, C Batlevi, ML Palomba, G Shah, RJ Lin… - Blood …, 2020 - ncbi.nlm.nih.gov
The prognosis of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma
(DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R …

Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies.

D Sermer, C Batlevi, ML Palomba, G Shah, RJ Lin… - Blood …, 2020 - europepmc.org
The prognosis of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma
(DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R …

Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies

D Sermer, C Batlevi, ML Palomba, G Shah, RJ Lin… - Blood Advances, 2020 - Elsevier
The prognosis of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma
(DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R …

Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies

D Sermer, C Batlevi, ML Palomba, G Shah… - Blood …, 2020 - pubmed.ncbi.nlm.nih.gov
The prognosis of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma
(DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R …